Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
2011 (English)In: Annals of Neurology, ISSN 0364-5134, E-ISSN 1531-8249, Vol. 69, no 1, 83-89 p.Article in journal (Refereed) Published
Our data demonstrate that natalizumab treatment reduces the accumulation of nerve injury in relapsing forms of MS. It is anticipated that highly effective anti-inflammatory treatment can reduce axonal loss, thereby preventing development of permanent neurological disability.
Place, publisher, year, edition, pages
2011. Vol. 69, no 1, 83-89 p.
fibrillary acidic protein; placebo-controlled trial; cerebrospinal-fluid; neurofilament light; disease-activity; lesion load; disability; MS; CSF
IdentifiersURN: urn:nbn:se:umu:diva-42424DOI: 10.1002/ana.22247PubMedID: 21280078OAI: oai:DiVA.org:umu-42424DiVA: diva2:409221